Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03511534

Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder

The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

OCD

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University

Stanford, California, 94305, United States

About this study

After completing one of the active clinical studies participants have the option to enroll in this protocol that offers open treatment.

The goal is to compare two forms of current standard treatments, psychotherapy vs pharmacotherapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to speak and understand English
  • Capacity to consent (e.g. as determined by assessing the patient's understanding of the risks, benefits, and procedures of the study)
  • Completed an active study protocol at the Rodriguez Lab at Stanford University

Exclusion criteria

  • Children younger than 18
  • Active suicidality

Treatment and study plan

Psychotherapy

Behavioral

Evidenced based psychotherapy by a trained psychologist

Pharmacotherapy

Other

Pharmacotherapy by a psychiatrist

Primary outcomes

  1. Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

    Time frame: Up to 14 weeks

    Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start
2017
Primary completion
2026
Study completion
2026
First posted
Apr 30, 2018
Registry last updated
Jul 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.